Arca
Skip to content

CT-P43: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761338's history or Celltrion's company page.

On Sep 30, 2024, FDA declined to approve CT-P43 (BLA 761338) from Celltrion Inc. in its present form, citing product quality microbiology, product quality. The application was later approved.

  • Letter date: Sep 30, 2024
  • Application: BLA 761338
  • Since then: Approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Product quality microbiologyProduct quality

The Letter

Text from openFDA

(1) The bacterial retention study is inadequate for the CT-P43 drug product, 130 mg/26 mL (5 mg/mL) single-dose vial for IV Repeat the bacterial retention study of the (2) The container closure integrity test (CCIT) dye ingress method used for stability testin...… openFDA did not return the full text just now. Open it in the letter search.

Celltrion's Other Letters

Newest first
  • BLA 761377Mar 26, 2025 · BLA 761377 · not approved
  • BLA 761377Jun 27, 2024 · BLA 761377 · not approved
  • CT-P6Mar 30, 2018 · BLA 761091 · later approved
  • CT-P10Feb 28, 2018 · BLA 761088 · later approved

Record

Company
Celltrion Inc.
Application
BLA 761338
Status in openFDA
Approved
Review division
Division of Dermatology and Dentistry

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.